Dr. Andrew Stadnyk, PhD
Research Investigator, Maritime Intestinal Research Alliance - pediatrics, http://mirapeds.ca/
Professor, Division of Gastroenterology & Nutrition, Department of Pediatrics and Department of Microbiology & Immunology, Faculty of Medicine, Dalhousie University; Scientific Staff, IWK Health Centre
Mucosal inflammation, digestive system diseases, oral and intestinal mucositis, colon cancer, inflammatory bowel diseases, complement system
Unremitting inflammation is the leading risk factor for colon cancer. Accordingly, we have applied our discoveries related to inflammatory processes in the intestines to identify how inflammation contributes to the emergence of cancers (publication 1). Recently this included dissecting the inflammatory processes triggered by chemotherapeutic drugs (mucositis), in particular, the role of molecules from the complement system. We are the first to report that complement becomes activated during model mucositis in mice. (publication 2). Chronic complement activation also happens to favor cancer cell growth, so we are exploring how interrupting complement activation may mitigate mucositis while reducing cancer cell growth.
Involvement with BHCRI to date:Dr. Stadnyk is a Senior Scientist of BHCRI and a former Chair of the BHCRI Scientific Review Committee.
Contact:MIRA-lab, 7th flr Women’s building, IWK Health Centre, 5850 University Avenue, Halifax, NS, B3K 6R8
Stillie, R.M., Sapp, H. and Stadnyk, A.W. (2012). TNFR1 deficiency protects mice from colitis-associated colorectal cancer coupled with a decreased level of oxidative damage in the colon: implications for anti-TNF therapy of unremitting colitis. Journal of Cancer Therapy 3(6A):926-940.
Jain, U., Midgen, C.A., Woodruff, T. M., Schwaeble, W.J., Stover, C.M. and Stadnyk, A.W. (2017). Properdin deficiency protects from 5-fluorouracil induced small intestinal mucositis in a complement activation independent, IL-10 dependent mechanism. Clinical & Experimental Immunology 188:36-44.